查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1467741

2024-2032 年按藥物類型、癌症類型、配銷通路和地區分類的腫瘤生物相似藥市場報告

Oncology Biosimilars Market Report by Drug Type, Cancer Type, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球腫瘤生物相似藥市場規模達47億美元。

癌症是一種生活方式疾病，由於細胞異常生長而發生，並可能導致腫瘤的形成。目前，大多數有效的癌症治療都是基於生物藥物，也稱為生物製劑，包括標靶治療和免疫療法。這些藥物是利用活體生物體（包括細菌、酵母和動物或植物細胞）生產的，需要複雜的製造過程和較長的開發時間。因此，這些藥物的成本相對較高，從而增加了癌症治療的費用。為了降低治療價格，人們對開發品牌腫瘤生物製劑的生物相似藥的興趣不斷增加。這些生物相似藥在有效性和安全性方面與參考生物製劑高度相似，並且由於成本較低，可以幫助顯著減少癌症治療的支出。

多年來，老年人口數量的增加和環境惡化增加了全球癌症的盛行率。這些因素，加上癌症治療成本的不斷上漲，增加了全球醫療保健系統的負擔。因此，許多國家的管理當局正在促進生物相似藥的採用，作為成本控制措施。例如，美國食品和藥物管理局 (USFDA) 為醫生和患者開發了資訊材料，以對他們進行生物相似藥的教育。除此之外，負擔得起的藥物的可用性也與更早和更廣泛的治療使用以及改善患者的可及性有關。除此之外，腫瘤生物相似藥還可以增加產業競爭，因此有可能進一步壓低生物藥的價格。其他一些促進市場成長的因素包括品牌生物製劑專利即將到期以及生物相似藥製造商增加研發 (R&D) 活動。

本報告回答的關鍵問題：

  • 迄今為止，全球腫瘤生物相似藥市場表現如何，未來幾年將如何表現？
  • COVID-19 對全球腫瘤生物相似藥產業有何影響？
  • 全球腫瘤生物相似藥產業的主要區域市場有哪些？
  • 根據藥物類型分類的市場是怎麼樣的？
  • 根據癌症類型分類的市場是怎麼樣的？
  • 基於配銷通路的市場區隔是什麼？
  • 全球腫瘤生物相似藥產業價值鏈的各個階段是什麼？
  • 全球腫瘤生物相似藥產業的關鍵促進因素和挑戰是什麼？
  • 全球腫瘤生物相似藥產業的結構如何？
  • 全球腫瘤生物相似藥產業的競爭程度如何？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球腫瘤生物相似藥市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場區隔：依藥物類型
  • 市場區隔：按癌症類型
  • 市場區隔：按配銷通路
  • 市場區隔：按地區
  • 市場預測

第 6 章：市場區隔：依藥物類型

  • 單株抗體
    • 市場走向
    • 市場預測
  • 免疫調節劑
    • 市場走向
    • 市場預測
  • 粒細胞集落刺激因子
    • 市場走向
    • 市場預測
  • 造血劑
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 7 章：市場區隔：按癌症類型

  • 肺癌
    • 市場走向
    • 市場預測
  • 大腸直腸癌
    • 市場走向
    • 市場預測
  • 子宮頸癌
    • 市場走向
    • 市場預測
  • 乳癌
    • 市場走向
    • 市場預測
  • 腎癌
    • 市場走向
    • 市場預測
  • 胃癌
    • 市場走向
    • 市場預測
  • 腦癌
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：市場區隔：按配銷通路

  • 醫院藥房
    • 市場走向
    • 市場預測
  • 網路藥局
    • 市場走向
    • 市場預測
  • 零售藥局
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 歐洲
    • 市場走向
    • 市場預測
  • 亞太地區
    • 市場走向
    • 市場預測
  • 北美洲
    • 市場走向
    • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場預測
  • 拉丁美洲
    • 市場走向
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Biocon Limited
    • Celltrion Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Intas Pharmaceuticals Ltd.
    • STADA Arzneimittel AG
    • Pfizer Inc.
    • Apotex Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz International GmbH
    • BIOCAD Biotechnology Company
    • Mylan NV
    • F. Hoffmann-La Roche AG
Product Code: SR112024A1572

The global oncology biosimilars market size reached US$ 4.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 30.3 Billion by 2032, exhibiting a growth rate (CAGR) of 22.3% during 2024-2032.

Cancer is a lifestyle disease that occurs due to the abnormal growth of cells and may result in the formation of a tumor. At present, most of the effective cancer treatments are based on biological drugs, also known as biologics, and include targeted therapies as well as immunotherapies. These drugs are produced using living organisms, including bacteria, yeast, and animal or plant cells, and require complex manufacturing processes and long development time. As a result, the cost of these drugs is relatively higher, which adds to the expense of cancer treatment. To lower the price of treatment, the interest in the development of biosimilars of branded oncology biologics has been increasing. These biosimilars are highly similar to the reference biologics in terms of effectiveness and safety and can help in significantly reducing the expenditure on cancer treatment due to their lower cost.

Over the years, the rising number of geriatric population and environmental degradation have increased the prevalence of cancer across the globe. These factors, along with the inflating cost of cancer care, have increased the burden on healthcare systems worldwide. Consequently, governing authorities in numerous countries are promoting the uptake of biosimilars as a cost-containment measure. For instance, the United States Food and Drug Administration (USFDA) has developed information materials for physicians and patients to educate them about biosimilars. Apart from this, the availability of affordable medication has also been associated with earlier and wider therapy use as well as improved patient access. Besides this, oncology biosimilars can also increase industry competition, owing to which they have the potential to drive down the prices of biological drugs further. Some of the other growth-inducing factors for the market include approaching patent expiries of branded biologics and increasing research and development (R&D) activities by biosimilar manufacturers.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global oncology biosimilars market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on drug type, cancer type and distribution channel.

Breakup by Drug Type:

Monoclonal Antibody

Immunomodulators

G-CSF

Hematopoietic Agents

Others

Breakup by Cancer Type:

Lung Cancer

Colorectal Cancer

Cervical Cancer

Breast Cancer

Kidney Cancer

Stomach Cancer

Brain Cancer

Others

Breakup by Distribution Channel:

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Others

Breakup by Region:

Europe

Asia Pacific

North America

Middle East and Africa

Latin America

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being Biocon Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD Biotechnology Company, Mylan N.V., F. Hoffmann-La Roche AG, etc.

Key Questions Answered in This Report:

  • How has the global oncology biosimilars market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global oncology biosimilars industry?
  • What are the key regional markets in the global oncology biosimilars industry?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the cancer type?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the global oncology biosimilars industry?
  • What are the key driving factors and challenges in the global oncology biosimilars industry?
  • What is the structure of the global oncology biosimilars industry and who are the key players?
  • What is the degree of competition in the global oncology biosimilars industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Oncology Biosimilars Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Drug Type
  • 5.5 Market Breakup by Cancer Type
  • 5.6 Market Breakup by Distribution Channel
  • 5.7 Market Breakup by Region
  • 5.8 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Monoclonal Antibody
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Immunomodulators
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 G-CSF
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Hematopoietic Agents
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Cancer Type

  • 7.1 Lung Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Colorectal Cancer
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cervical Cancer
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Breast Cancer
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Kidney Cancer
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Stomach Cancer
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Brain Cancer
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast
  • 7.8 Others
    • 7.8.1 Market Trends
    • 7.8.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Online Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Retail Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 Europe
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 North America
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Middle East and Africa
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Latin America
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Biocon Limited
    • 14.3.2 Celltrion Inc.
    • 14.3.3 Dr. Reddy's Laboratories Ltd.
    • 14.3.4 Intas Pharmaceuticals Ltd.
    • 14.3.5 STADA Arzneimittel AG
    • 14.3.6 Pfizer Inc.
    • 14.3.7 Apotex Inc.
    • 14.3.8 Teva Pharmaceutical Industries Ltd.
    • 14.3.9 Sandoz International GmbH
    • 14.3.10 BIOCAD Biotechnology Company
    • 14.3.11 Mylan N.V.
    • 14.3.12 F. Hoffmann-La Roche AG

List of Figures

  • Figure 1: Global: Oncology Biosimilars Market: Major Drivers and Challenges
  • Figure 2: Global: Oncology Biosimilars Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Oncology Biosimilars Market: Breakup by Drug Type (in %), 2023
  • Figure 4: Global: Oncology Biosimilars Market: Breakup by Cancer Type (in %), 2023
  • Figure 5: Global: Oncology Biosimilars Market: Breakup by Distribution Channel (in %), 2023
  • Figure 6: Global: Oncology Biosimilars Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Oncology Biosimilars Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 8: Global: Oncology Biosimilars Industry: SWOT Analysis
  • Figure 9: Global: Oncology Biosimilars Industry: Value Chain Analysis
  • Figure 10: Global: Oncology Biosimilars Industry: Porter's Five Forces Analysis
  • Figure 11: Global: Oncology Biosimilars (Monoclonal Antibody) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Oncology Biosimilars (Monoclonal Antibody) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Oncology Biosimilars (Immunomodulators) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Oncology Biosimilars (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Oncology Biosimilars (G-CSF) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Oncology Biosimilars (G-CSF) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Oncology Biosimilars (Hematopoietic Agents) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Oncology Biosimilars (Hematopoietic Agents) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Oncology Biosimilars (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Oncology Biosimilars (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Oncology Biosimilars (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Oncology Biosimilars (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Oncology Biosimilars (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Oncology Biosimilars (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Oncology Biosimilars (Cervical Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Oncology Biosimilars (Cervical Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Oncology Biosimilars (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Oncology Biosimilars (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Oncology Biosimilars (Kidney Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Oncology Biosimilars (Kidney Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Oncology Biosimilars (Stomach Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Oncology Biosimilars (Stomach Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Oncology Biosimilars (Brain Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Oncology Biosimilars (Brain Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Oncology Biosimilars (Other Cancer Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Oncology Biosimilars (Other Cancer Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Oncology Biosimilars Market: Sales through Hospital Pharmacies (in Million US$), 2018 & 2023
  • Figure 38: Global: Oncology Biosimilars Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2024-2032
  • Figure 39: Global: Oncology Biosimilars Market: Sales through Online Pharmacies (in Million US$), 2018 & 2023
  • Figure 40: Global: Oncology Biosimilars Market Forecast: Sales through Online Pharmacies (in Million US$), 2024-2032
  • Figure 41: Global: Oncology Biosimilars Market: Sales through Retail Pharmacies (in Million US$), 2018 & 2023
  • Figure 42: Global: Oncology Biosimilars Market Forecast: Sales through Retail Pharmacies (in Million US$), 2024-2032
  • Figure 43: Global: Oncology Biosimilars Market: Sales through Other Distribution Channels (in Million US$), 2018 & 2023
  • Figure 44: Global: Oncology Biosimilars Market Forecast: Sales through Other Distribution Channels (in Million US$), 2024-2032
  • Figure 45: Europe: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Europe: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Asia Pacific: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Asia Pacific: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: North America: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: North America: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Middle East and Africa: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Middle East and Africa: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Latin America: Oncology Biosimilars Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Latin America: Oncology Biosimilars Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

  • Table 1: Global: Oncology Biosimilars Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Oncology Biosimilars Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 3: Global: Oncology Biosimilars Market Forecast: Breakup by Cancer Type (in Million US$), 2024-2032
  • Table 4: Global: Oncology Biosimilars Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Oncology Biosimilars Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Oncology Biosimilars Market Structure
  • Table 7: Global: Oncology Biosimilars Market: Key Players